New Social Media Guidance From US FDA May Be On The Horizon
Executive Summary
Future guidances may address information on healthcare sites and individual influencers and endorsers. ‘It is a difficult time to make any predictions about the timing of guidance,’ but the agency is looking at these issues, CDER deputy center director Grail Sipes tells FDLI conference.
You may also be interested in...
Despite Few Actions On Rx Drug Promos, US FDA Increased Engagement With Stakeholders Last Year
Office of Prescription Drug Promotion issued six enforcement letters and launched three research projects in 2021. There were more internal changes as the office switched to electronic submissions of promotional materials and went through year-end reorganization.
Top US FDA Drug Policy Leader Leaving For White House Detail
Grail Sipes, CDER deputy center director for regulatory policy, will move to the Executive Office of the President next month.
US FDA Actions On Rx Drug Promos Covered New Territory Last Year
Office of Prescription Drug Promotion issued just six letters citing companies for improper drug promotion in 2020, including the placement of safety information in an email and making unfounded COVID-19 claims. New research projects focus on celebrity endorsements, medical conference materials.